Michiel Lodder
Amministratore Delegato presso 20Med Therapeutics BV
Profilo
Michiel Lodder is currently the Chief Executive Officer at 20Med Therapeutics BV since 2016 and the Vice President-Business Development at LanthioPep BV since 2013.
He previously worked as the Principal at Octoplus AB, Chief Business Officer at Pepscan Therapeutics BV, and Vice President-Business Development at Lanthio Pharma BV.
Dr. Lodder holds a doctorate degree from the University of Virginia and a graduate degree from the University of Leiden.
Posizioni attive di Michiel Lodder
| Società | Posizione | Inizio |
|---|---|---|
LanthioPep BV
 LanthioPep BV Medical SpecialtiesHealth Technology LanthioPep BV specializes in vivo stability of therapeutic and diagnostic imaging peptides. Its products include pancyte, lanthi apelin and galanin agonist. The company is headquartered in Groningen, the Netherlands. | Corporate Officer/Principal | 01/03/2013 |
20Med Therapeutics BV
 20Med Therapeutics BV BiotechnologyHealth Technology 20Med Therapeutics BV operates as a biomedical company. It focuses on the development of biodegradable materials for biomedical applications and multifunctional nanosystems for controlled drug and gene delivery. The company was founded by Johan F. J. Engbersen in 2011 and is headquartered in Enschede, the Netherlands. | Amministratore Delegato | 01/01/2016 |
Precedenti posizioni note di Michiel Lodder
| Società | Posizione | Fine |
|---|---|---|
Lanthio Pharma BV
 Lanthio Pharma BV Medical SpecialtiesHealth Technology Lanthio Pharma BV focuses on discovering and developing lantipeptides for the generation of novel peptide therapeutics. Its product is a lanthionine-stabilized specific agonist of the AT2 receptor, which has great potential in diseases where tissue protection is important, like fibrosis. The company was founded in 2010 and is headquartered in Groningen, the Netherlands. | Corporate Officer/Principal | - |
Octoplus AB
 Octoplus AB Information Technology ServicesTechnology Services Part of CGI, Inc., Octoplus AB provides Internet consulting services. The company is based in Helsingborg, Sweden. Octoplus was acquired by WM-data AB on March 09, 2000. | Corporate Officer/Principal | - |
Pepscan Therapeutics BV
 Pepscan Therapeutics BV Pharmaceuticals: MajorHealth Technology Pepscan Therapeutics BV develops immunotherapeutic products in oncology. The company was founded in 2000 and is headquartered in Lelystad, the Netherlands. | Corporate Officer/Principal | - |
Formazione di Michiel Lodder
| University of Virginia | Doctorate Degree |
| University of Leiden | Graduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 5 |
|---|---|
Octoplus AB
Octoplus AB Information Technology ServicesTechnology Services Part of CGI, Inc., Octoplus AB provides Internet consulting services. The company is based in Helsingborg, Sweden. Octoplus was acquired by WM-data AB on March 09, 2000. | Technology Services |
Pepscan Therapeutics BV
Pepscan Therapeutics BV Pharmaceuticals: MajorHealth Technology Pepscan Therapeutics BV develops immunotherapeutic products in oncology. The company was founded in 2000 and is headquartered in Lelystad, the Netherlands. | Health Technology |
LanthioPep BV
LanthioPep BV Medical SpecialtiesHealth Technology LanthioPep BV specializes in vivo stability of therapeutic and diagnostic imaging peptides. Its products include pancyte, lanthi apelin and galanin agonist. The company is headquartered in Groningen, the Netherlands. | Health Technology |
20Med Therapeutics BV
20Med Therapeutics BV BiotechnologyHealth Technology 20Med Therapeutics BV operates as a biomedical company. It focuses on the development of biodegradable materials for biomedical applications and multifunctional nanosystems for controlled drug and gene delivery. The company was founded by Johan F. J. Engbersen in 2011 and is headquartered in Enschede, the Netherlands. | Health Technology |
Lanthio Pharma BV
Lanthio Pharma BV Medical SpecialtiesHealth Technology Lanthio Pharma BV focuses on discovering and developing lantipeptides for the generation of novel peptide therapeutics. Its product is a lanthionine-stabilized specific agonist of the AT2 receptor, which has great potential in diseases where tissue protection is important, like fibrosis. The company was founded in 2010 and is headquartered in Groningen, the Netherlands. | Health Technology |
- Borsa valori
- Insiders
- Michiel Lodder
